Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

HealthDay News — The US Department of Health and Human Services has announced a major initiative to reform the organ transplant system. This action follows an investigation by the Health Resources and ...

Six or 9 months of bedaquiline, delamanid, linezolid, and clofazimine was not noninferior to longer standard of care.

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

HealthDay News — Small-group professional coaching can reduce physician burnout rates by up to nearly 30%, according to a study published online July 11 in the Journal of General Internal Medicine.

In addition to oral administration, Spritam may now be administered via nasogastric tube (NG tube) or gastrostomy tube (G tube). The approval was based on data confirming that the drug can be ...

The Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 10-1 against the approval of brexpiprazole in combination with sertraline for the treatment of adults ...

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.

HealthDay News — Patients with osteoporosis who suffer a fragility fracture at age 80 years or older have better 5-year outcomes if they receive treatment for osteoporosis, according to a study ...

Estimated risk ratio was lower with GLP-1 receptor agonists for those younger than 75 years, but was no different for those aged 75 years or older ...

Overall, 12.4, 9.1, and 1.3% of urgent care visits led to antibiotic, glucocorticoid, and opioid prescription fills, respectively.